Now Playing
Opinion|Videos|March 10, 2025
Drug Delivery Systems in NMIBC
Author(s)Karim Chamie, MD, MSHS
An expert discusses how non–muscle invasive bladder cancer (NMIBC) treatment involves evolving delivery systems, transitioning from traditional systemic and intravesical approaches to advanced targeted technologies. Current research focuses on innovative platforms such as nanoparticle carriers, thermosensitive hydrogels, and personalized molecular delivery mechanisms to improve therapeutic efficacy and minimize systemic toxicity.
Advertisement
Video content above is prompted by the following:
- Please provide a brief overview of delivery systems that are available to patients for treatment of NMIBC (ie, systemic IV delivery and bladder delivery systems).
- Discuss ongoing studies with investigational delivery systems in different subpopulations of NMIBC.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
FDA approves ProVee System for benign prostatic hyperplasia
4
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
5
